Bonesupport reported some very promising results in the latest report, but the market has not yet, in my opinion, realised its value. It actually gave no effect at all on the stock.
ABG sundal Collier recently raised the target price to 53kr from 30kr.
ABG Sundal Collier höjer riktkursen för Bonesupport till 53 kronor från 30 kronor. Rekommendationen köp upprepas. Det framgår av en analys.
Carnegie is acting as sell block at the moment but when they loosen their sell pressure, the revaluation can begin.
A triangle formation with a raising introduction is getting closer to its apex and if the stock breaks the triangle roof, a price of 46kr is justified.
Overall there is both technical and fundamental support at this level (30kr-35kr) and is in my opinion undervalued.
---
This is not a recommendation, but rather my speculations and personal thoughts.
You should always make your own analysis before buying any stock.
---